Jeff Zygouras
Director of Finance/CFO at NEUPATH HEALTH INC.
Net worth: 4 972 $ as of 2024-04-29
Jeff Zygouras active positions
Companies | Position | Start | End |
---|---|---|---|
NEUPATH HEALTH INC. | Corporate Secretary | 2022-03-16 | - |
Director of Finance/CFO | 2021-06-29 | - | |
Comptroller/Controller/Auditor | 2018-12-31 | 2021-06-29 |
Career history of Jeff Zygouras
Former positions of Jeff Zygouras
Companies | Position | Start | End |
---|---|---|---|
NUVO PHARMACEUTICALS INC. | Corporate Officer/Principal | 2018-08-31 | 2019-05-31 |
CRESCITA THERAPEUTICS INC. | Corporate Officer/Principal | 2016-02-29 | 2017-05-31 |
Ernst & Young, Inc.
Ernst & Young, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young, Inc. is a professional services firm based in Toronto, Canada. The Canadian company provides a range of services and solutions to help clients transform, grow, and operate. The company's services include strategy consulting, analytics consulting, people advisory services, transactions and corporate finance, assurance, tax planning, and legal services. The company also offers advanced technology, audit technology, tax technology, and managed services. Ernst & Young is committed to creating long-term value for all stakeholders and building a better working world. The CEO of the company is Jad Shimaly. | Corporate Officer/Principal | - | - |
Training of Jeff Zygouras
University of Toronto | Graduate Degree |
Statistics
International
Canada | 6 |
Operational
Corporate Officer/Principal | 3 |
Comptroller/Controller/Auditor | 1 |
Director of Finance/CFO | 1 |
Sectoral
Health Technology | 3 |
Finance | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
NEUPATH HEALTH INC. | Finance |
CRESCITA THERAPEUTICS INC. | Health Technology |
Private companies | 2 |
---|---|
Nuvo Pharmaceuticals, Inc.
Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
Ernst & Young, Inc.
Ernst & Young, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Ernst & Young, Inc. is a professional services firm based in Toronto, Canada. The Canadian company provides a range of services and solutions to help clients transform, grow, and operate. The company's services include strategy consulting, analytics consulting, people advisory services, transactions and corporate finance, assurance, tax planning, and legal services. The company also offers advanced technology, audit technology, tax technology, and managed services. Ernst & Young is committed to creating long-term value for all stakeholders and building a better working world. The CEO of the company is Jad Shimaly. | Commercial Services |
- Stock Market
- Insiders
- Jeff Zygouras
- Experience